5 ms·
i don't know what else mylan makes, or how much is epipens, or whatever, but if we look at their 2017 financials, and removed all R&D, they'd have had a profit
by sigstoat 8y ago
i don't know what else mylan makes, or how much is epipens, or whatever, but if we look at their 2017 financials, and removed all R&D, they'd have had a profit of ~1.2B on total revenue of ~11.9B. so they could shave an average of 10% off the cost of their product line and still break even.
maybe there are other places costs can be cut, but as you'd expected ( http://www.aei.org/publication/the-public-thinks-the-average-company-makes-a-36-profit-margin-which-is-about-5x-too-high-part-ii/ http://www.aei.org/publication/the-public-thinks-the-average... ) they're not wildly more profitable than other companies.
- pbhjpbhj 8y agoWhat % was spent on revenue; a while back it came out that drug companies were spending more on marketing than on R&D whilst arguing they needed special protections because of the high cost of R&D. A low profit company, charging a distant lower amount for probably rely on word-of-mouth + news features to some extent. Also, you can save a lot by not paying shareholders and C-suiters massive amounts.
- pas 8y agoShareholders are paid from these profits only, no?